biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE
Monte Rosa Therapeutics
Monte Rosa Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 213
- Programs
- 7
- Drugs
- 14
- Patents
- 72
Monte Rosa Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Monte Rosa Therapeutics.
Monte Rosa Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Cabergoline 1 MG
Monte Rosa Therapeutics
Lactation Suppressed
1 trial -
F106-CT01
Monte Rosa Therapeutics
Bile acid diarrhoea
1 trial -
Oral MRT-2359
Monte Rosa Therapeutics
NSCLC
1 trial -
MRT-6160
Monte Rosa Therapeutics
Healthy Volunteers
1 trial -
MRT-8102
Monte Rosa Therapeutics
Healthy Volunteers
1 trial -
Temozolomide
Monte Rosa Therapeutics
Brain Neoplasms, Malignant, Primary
1 trial -
Vyndaqel 61 mg soft capsules
Monte Rosa Therapeutics
Transthyretin cardiac amyloidosis
1 trial
Frequently asked questions
How many clinical projects does Monte Rosa Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.